Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Building a nice base and support here. Tape is showing the stock is in firmer hands.
No more dilution for 90 days. FDA approval news coming.
What do you think they will do with all those shares at 5 to 6 cents. They will jam/squeeze it up knowing no additional shares are coming. IMO, hedgies are on this.
I do believe it can jam above $1 if news hits at the right moment. For time being throw the fundamentals out. It didn't go down to nickel on fundamentals anyway.
33% may have converted or not is irrelevant. What is relevant is the majority of current outstanding warrant holders have consented to the clarification of conversion and subsequent failure by the company to deliver those shares because of lack of authorized shares.
<<<<On September 21, 2015, the Company ENTERED into an amendment agreement (the “Warrant Amendment”) with the holders of more than 66.7% of the outstanding Series C Warrants to clarify the mechanical procedures and process with respect to the first Authorized Share Failure and the corresponding Grace Period, which were inadvertently omitted from the initial form of Series C Warrant.>>>>
If some of those minority c warrant holders are net short, they better request conversions before the A/S max, because they won't be able to cover with those shares for 90 days after the A/S max. With squeeze and float lock, share price could be multiple of where they shorted. With some good news, FDA approval of additional tests, these shorts could be squeezed til their eyes pop out.
Company stated they were able to pay for warrant conversions in shares of common stock or cash. Since the company was still losing money, conserving $15mil cash on hand was also important as they need the funding to ramp up sales and equipment manufacturing.
When the company realized some warrant holders were out to destroy the common shares and basically take over the company as the majority share holders, they went out and hired RCP.
Today's PR tells me not all warrant holders are scumbags. I say scumbags because they didn't have to drive the price down like this. They do not get more money if the share price is cheaper. Only if they short and pay with converted shares.
Put aside all the noise about conversions and dilutions. This company has potential to produce very nice recurring revenue as they place more analyzers in the clinics and hospitals and more tests performed with additional FDA approved tests.
It means majority. Done deal!
Don't believe all C warrant holders are converting. Only way for them to make more than the face value of the warrant is if they short and deliver their shares to cover.
Company has hired RCP to reorganize C warrants. Watch the tape for sign of imminent deal. When this thing runs other way, you know the deal will be announced.
Not a scam company here. This company is no different than any other bio in term of cash burn in order to get that elusive revenue base to generate positive cash flow.
The problem here is two fold.
One is the ineptitude of ceo and cfo of managing financing mechanism. Big blame also goes to the board for not recognizing potential problem with cashless warrants and its impact on share price and to future financing, which the company will need.
The other is, also related to first, that is they got financing from really low bottom of the barrel investors. Whoever did the financing did lousy job attracting quality investors.
Today's PR tells me the company does understand the gravity of the situation and they want to stop to this madness. Prior PR indicates the company at its discretion can redeem warrants for stock or cash. Company with the help of RCP may get other backer(s) now that the company's business developments are on track according to the company. I personally do like the tech and the potential for revenue growth.
Recently, CLTX, after failing its drug studies was left for dead, running out of cash was able to do reverse merger with a small Swiss bio. Brokers were able to get $75mil financing at $150mil valuation from well known bio investors. Stock ran from around $0.6 to over $5. Different situation, but does underscore the importance of type of backers or investors.
Lots money are out there for bios. Company should be able to attract investors looking for emerging opportunities. Company needs to find alternate financing to pay off warrant holders. Any investor at this point is better than these warrant holders.
Shorting should wane as shorts could be hit with an anti-dilutive or less dilutive financing mechanism any morning that could send shares soaring.
Calling bottom here. Good time to pick up additional shares.
IMO, liquid biopsy theme will play out huge coming years.
Lung cancer is the leading cause of cancer-related death among men and women. According to data from the National Cancer Institute in 2013, an estimated 228,190 Americans will be diagnosed with lung cancer, and 159,480 would die from the disease. About 85 percent of lung cancers are non-small cell lung cancers (NSCLC), making it the most common type of lung cancer. EGFR gene mutations are present in the tumors of about 10 percent of NSCLC patients, with the majority of these gene mutations expressing EGFR in exon 19 deletions or exon 21 L858R substitutions.
$1k per test, that's potential $228mil in rev. That's big.
Biocept Expands Non-Small Cell Lung Cancer Diagnostic Capabilities for EGFR Mutations
http://finance.yahoo.com/news/biocept-expands-non-small-cell-123000496.html
Nice pre-earnings run. Hope some good development or progress on sales/rev traction on Liquid Biopsy from CC this afternoon.
SPO is done deal at $4.15. In microcap land, SPO is done at a huge discount to entice institutional investors and allow brokers to manage offerings.
Buying stock after big hair cut below SPO is a good strategy because the fall is temporary and the price retraces to SPO price and above.
Bot yesterday at $3.21 and may add more today.
Shorts getting gored.
Liquid biopsy is new breakthrough in cancer diagnostics. It will be one of the biggest investment themes. Shorts ignoring that will get burned badly.
Longs if you buy into that theme, you will make big money.
Liquid biopsy will be one of the biggest investment themes in biotech. Potential revenues are in the billions. Big money will flow into this sector. Biocept is at the forefront.
Once some well know bio hedge funds buy into Biocept, it will be trading in double digits.
Buy this baby here. Once this baby grows up, it will be too expensive.
Excellent article. thx
Added lil more shares. Lets see how it closes today. Next couple of days this volatility will die and folks will be focused on the science. They will be bullish for the long term.
Still holding mine. Needs to get over shorts/momo players. It's dog fight out there. I bot the science and potential, so my outlook is long term.
If medicare approves coverage, then the price will head to the moon.
Sold at the open and bot back at $3.88
Now I have 1400 more shares. Up we go.
Too many sheep and lemmings out there. Wonder how many of them actually read presentations and sec filings.
CLRX closed $2.25 and then the co. dropped the ATM offering bomb.
I've known CLRX for long time. Trust me they don't have good product or revenue model. They provide cloud based information to physicians and patients. Only thing common with BIOC is they provide some genetic based information.
No, it's dipping in sympathy with CLRX, doing another dilution via ATM offering.
CLRX is pos and its revenue potential doesn't even come near BIOC.
Some just taking few chips off the table. No worries here.
There is a real possibility a pharma, biotech or diagnostic co may want a piece of the company.
I posted yesterday.
"You should consider buying back and holding. This one has multi bagger written all over it"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111077298
Lots micro gene biotechs are running this morning. WGBS and CLRX. Those 2 companies are running in sympathy with BIOC, but they don't really have anything under the hood. I would not touch them unless if you're in for a quick scalp.
Stick with the leader.....$bioc
No chances of getting burned. But will watch.
For sure...I think many folks will get stopped out either long or short. Me, might just watch the show.
$bioc has much better potential than $gene. Biocepts liquid biopsies for cancer is used for most prevalent solid tumors such as breast, gastric and non-small lung cancer. Melanoma, colorectal and prostate in the pipeline. Ceo of Illumina said liquid biopsies could be worth $40bil.
$BIOC up big pre-market.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110844610
I hope someone looked into it and bot when I posted it.
Currently, only some private payers are reimbursing Biocept's tests. With the latest funding, co is increasing sales efforts to increase adoption. The big catalyst is the Medicare coverage. It's not covered on Medicare, but I am certain in the future it will be covered. Less than couple of hundred dollars vs avg $14k for tissue biopsy, medicare has all the incentive to adopt liquid biopsies.
17.6k
Lots shorts eyeing this, but I am afraid they will be in a world of hurt. It will be very volatile with heavy volume.
I would rather like to see few days of trading around $4-5 range before making charge toward all time high.
In at $1.19 avg after SPO.
Yesterday morning I suggested buying and holding.
<<Liquid biopsy will go mainstream soon. Biocept is at starting gate. I am very long for Biocept double digits and beyond.
Remember "liquid biopsy">>
Ceo of Illumina, Jay Flatley, said liquid biopsy will be "stethoscope" of future cancer treatment and predicted this market has $40 billion potential.
Now you know why Biocept is trading this way after confirmatory news from Columbia University.
This co. IPO'd at $10 last year and went down hard. In that time co. further developed their test and now include breast and non-small lung cancer. IMO, their timing was bit premature. Now, several sources are predicting liquid biopsies are about to go mainstream.
Company has test pipeline for melanoma, colorectal and prostate. Otherwise, Biocept's liquid biopsy works on most prevalent solid tumors.
Why is it potentially $40billion opportunity? Because these tests would be recurring tests for newly diagnosed as well as millions living with cancer, just like one would get blood test for high cholesterol or hepatitis. If you were a cancer patient, wouldn't you want to do blood test for circulating tumor cells (CTCs) for the cancer status and to plan treatment instead of waiting and thinking the tumor is gone but to find out later it metastasized.
I believe liquid biopsy is medical breakthrough that will fundamentally change how we diagnose and monitor cancers.
Biocept's liquid biopsy is a game changer. buy and hold to double digits
You should consider buying back and holding. This one has multi bagger written all over it.
Ceo of Illumina said liquid biopsy market is worth potentially $40billion.
IMO, Biocept will trade over double digits possibly by the end of year or by next year.
Liquid biopsy will go mainstream soon. Biocept is at starting gate. I am very long for Biocept double digits and beyond.
Remember "liquid biopsy"
$BIOC. another $GENE in the making. genetic cancer detection to improve cancer treatment outcome. Financing closing today $1.25. Very low float. IPO'd last year at $10. Been crushed, however their R&D made great stride and it's in commercial stage.
If that rumor is true, that is unbelievable. These guys are very brazen to say the least. How would the market react if FXCM picks up Alpari UK cheap?
Might just have to hold to see what happens. IMO, these guys have not thrown in the towel yet.
Today is the first day of b/o. The herd will descend tomorrow.
PR contains juicy "body worn/wearable camera" angle. Low mk/float, this might explode next couple of days.
Pick a spot and enjoy the ride.